300871.SZ
HVSEN Biotechnology Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 22.67
−2.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 1.7B | 1.2B | 1.0B | 1.0B |
| Cost of Revenue | 1.2B | 1.2B | 1.0B | 806.5M | 797.5M |
| Gross Profit | 586.0M | 521.0M | 196.1M | 213.3M | 225.4M |
| Operating Expenses | |||||
| R&D Expense | 89.8M | 79.8M | 55.8M | 44.6M | 40.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 69.5M | 66.5M | 59.5M | 75.7M | 54.0M |
| Selling & Marketing Expense | 89.3M | 83.9M | 59.3M | 55.6M | 48.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 264.7M | 253.9M | 225.5M | 209.9M | 165.6M |
| Cost and Expenses | 1.4B | 1.4B | 1.2B | 1.0B | 963.1M |
| Operating Income (EBIT) | 326.9M | 290.5M | (29.1M) | 15.1M | 59.2M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 325.3M | 288.7M | (29.0M) | 12.4M | 56.7M |
| Income Tax Expense | 38.4M | 35.2M | (9.2M) | (4.3M) | 4.0M |
| Bottom Line | |||||
| Net Income | 286.3M | 253.2M | (20.2M) | 16.8M | 52.7M |
| Earnings from Cont. Ops | 287.0M | 253.5M | (19.8M) | 16.8M | 52.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 286.3M | 253.2M | (20.2M) | 16.8M | 52.7M |
| Per Share | |||||
| Basic EPS | CN¥1.52 | CN¥1.33 | (CN¥0.12) | CN¥0.10 | CN¥0.32 |
| Diluted EPS | CN¥1.52 | CN¥1.29 | (CN¥0.12) | CN¥0.10 | CN¥0.32 |
| Revenue Per Share | CN¥8.60 | CN¥8.87 | CN¥7.24 | CN¥6.14 | CN¥6.18 |
| Shares | |||||
| Basic Shares Outstanding | 202.3M | 189.6M | 165.9M | 166.0M | 165.4M |
| Diluted Shares Outstanding | 202.3M | 189.6M | 165.9M | 166.0M | 165.4M |
| Profitability Metrics | |||||
| EBITDA | — | 411.8M | 85.0M | 136.1M | 121.9M |
| D&A | — | 121.3M | 114.0M | 121.0M | 62.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026